Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Accured Expenses (2020 - 2026)

Immuneering's Change in Accured Expenses history spans 7 years, with the latest figure at -$247323.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 84.63% to -$247323.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 million, a 190.2% increase, with the full-year FY2025 number at $57848.0, up 128.8% from a year prior.
  • Change in Accured Expenses came in at -$247323.0 for Q1 2026, down from $211424.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $1.8 million in Q3 2022, with the low at -$1.8 million in Q2 2022.
  • Historically, Change in Accured Expenses has averaged $21967.4 across 5 years, with a median of $30350.5 in 2023.
  • Biggest five-year swings in Change in Accured Expenses: crashed 3712.3% in 2024 and later soared 29546.24% in 2025.
  • Year by year, Change in Accured Expenses stood at -$24766.0 in 2022, then surged by 2770.14% to $661288.0 in 2023, then crashed by 100.11% to -$718.0 in 2024, then surged by 29546.24% to $211424.0 in 2025, then tumbled by 216.98% to -$247323.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for IMRX at -$247323.0 in Q1 2026, $211424.0 in Q4 2025, and $304594.0 in Q3 2025.